The combination of BRAF and MEK inhibitors, used to target the MAPK pathway, with anti–PD-1/PD-L1 has been shown to increase anti-tumor immunity and decrease exhaustion and apoptosis. This evidence concerns the gene PDCD1 and neoplasm.